Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Jelic, S ^a   Sotiropoulos, G C ^b  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; ALPHA INTERFERON; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BEVACIZUMAB; CALCINEURIN INHIBITOR; CISPLATIN; CORTICOSTEROID; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GELFOAM; GEMCITABINE; INTERFERON; IODINATED POPPYSEED OIL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; OXALIPLATIN; PLACEBO; RAPAMYCIN; SORAFENIB; SUNITINIB; TAMOXIFEN; UNINDEXED DRUG; YTTRIUM 90;

ABLATION THERAPY; ADVANCED CANCER; ALGORITHM; ARTICLE; ARTIFICIAL EMBOLISM; ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; ECHOGRAPHY; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER SURGERY; LIVER TRANSPLANTATION; MICROWAVE THERAPY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; X RAY;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77954333876     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq166     Document Type: Article

References (42)

1. Tanaka H, Tsukuma H, Kasahara A et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000; 87: 741-749.
2. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
3. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
4. Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000; 31: 1019-1021.
5. Leung TWT, Patt YZ, Lau W-Y et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5: 1676-1681.
6. Bergsland EK, Venook AP. Hepatocellular carcinoma. Curr Opin Oncol 2000; 12: 357-361.
7. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
8. Simonetti RG, Camma C, Fiorello F et al. Hepatocellular carcinoma: a worldwide problem and the major risk factors. Dig Dis Sci 1991; 36: 962-972.
9. Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg 1993; 217: 149-154.
10. Mathurin P, Rixe O, Carbonell N et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma-an impossible metaanalysis? Aliment Pharmacol Ther 1998; 12: 111-126.
11. Tanaka K, Nakamura S, Numata K et al. The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis. Cancer 1998; 82: 78-85.
12. Fong Y, Sun RL, Jarnagin W et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229: 790-799.
13. Hemming AW, Cattral MS, Reed AI et al. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001; 233: 652-659.
14. Zhou XD, Tang ZY. Cryotherapy for primary liver cancer. Semin Surg Oncol 1998; 14: 171-174.
15. Llovet JM, Ricci S, Mazzaferro V et al. for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N EnglJ Med 2008; 359: 378-390.
16. Yeo W, Mok TS, Zee B et al. A randomized phase III study of docorubicin vs cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-1538.
17. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
18. Vogl T, Zangos S, Balzer J et al. Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results. Rofo 2007; 179: 1113-1126.
19. Livraghi T, Bolondi L, Lazzaroni S et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 1992; 69: 925-929.
20. Curley SA, Izzo F, Ellis LM et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000; 232: 381-391.
21. Mazzaferro V, Llovet JM, Miceli R et al. for the Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
22. Sotiropoulos GC, Molmenti EP, Lang H. Milan criteria, up-to-seven criteria, and the illusion of a rescue package for patients with liver cancer. Lancet Oncol 2009; 10: 207-208.
23. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134: 1342-1351.
24. Sotiropoulos GC, Molmenti EP, Lang H. Liver transplantation for hepatocellular carcinoma in the MELD era: leading roles of MELD score, AFP level, and recipient age as predictors of survival. Dig Dis Sci 2009; 54: 917.
25. Sotiropoulos GC, Drühe N, Sgourakis G et al. Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach? Dig Dis Sci 2009; 54: 2264-2273.
26. Timm S, Sotiropoulos GC, Draier M et al. Selective transarterial chemoembolization of advanced hepatocellular carcinomas: a reasonable palliative option. Transplant Proc 2008; 40: 3179-3181.
27. Sotiropoulos GC, Radtke A, Schmitz KJ et al. Liver transplantation in the setting of hepatocellular carcinoma and portal vein thrombosis: a challenging dilemma? Dig Dis Sci 2008; 53: 1994-1999.
28. Sotiropoulos GC, Molmenti EP, Lösch C et al. Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases. Eur J Med Res 2007; 12: 527-534.
29. Sotiropoulos GC, Treckmann JW, Molmenti EP et al. Salvage live donor liver transplantation for a second recurrence of hepatocellular carcinoma. Transpl Int 2008; 21: 182-185.
30. Lang H, Sotiropoulos GC, Brokalaki EI et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007; 205: 27-36.
31. Sotiropoulos GC, Molmenti EP, Omar OS et al. Liver transplantation for hepatocellular carcinoma in patients beyond the Milan but within the UCSF criteria. Eur J Med Res 2006; 11: 467-470.
32. Sotiropoulos GC, Lang H, Frühauf NR et al. Split liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 2006; 53: 764-767.
33. Sotiropoulos GC, Lang H, Frilling A et al. Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature. Hepatogastroenterology 2006; 53: 322-329.
34. Sotiropoulos GC, Malago M, Molmenti EP et al. Disease course after liver transplantation for hepatocellular carcinoma in patients with complete tumor necrosis in liver explants after performance of bridging treatments. Eur J Med Res 2005; 10: 539-542.
35. Sotiropoulos GC, Paul A, Molmenti E et al. Liver transplantation for hepatocellular carcinoma in cirrhosis within the Eurotransplant area: an additional option with 'livers that nobody wants'. Transplantation 2005; 80: 897-902.
36. Sotiropoulos GC, Malagó M, Molmenti E et al. Efficacy of transarterial chemoembolization prior to liver transplantation for hepatocellular carcinoma as found in pathology. Hepatogastroenterology 2005; 52: 329-332.
37. Sotiropoulos GC, Malagó M, Molmenti E et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? Transplantation 2005; 79: 483-487.
38. Ravaioli M, Grazi GL, Ercolani G et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 2004; 78: 1780-1786.
39. Mazzaferro V, Battiston C, Perrone S et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240: 900-909.
40. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765-774.
41. Kulik LM, Atassi B, van Holsbeeck L et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. Surg Oncol 2006; 94: 572-586.
42. Lewandowski RJ, Kulik LM, Riaz A et al. Comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9: 1920-1928.